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Introduction
Enthesitis related arthritis (ERA) is a subcategory of
juvenile idiopathic arthritis (JIA) which primarily affects
peripheral joints and entheses but also can involve the
sacroiliac joints and spine. It causes long-term effects
on both physical and quality aspects of a child’s life.
Adalimumab (ADA) has been previously demonstrated
to be effective in polyarticular JIA.
Objectives
To evaluate the efficacy and safety of adalimumab com-
pared to placebo in children and adolescents with ERA.
Methods
This is a phase 3, multicenter, randomized, double-blind
(DB) study in patients (pts) aged ≥6 to <18 years (yr)
with ERA (ILAR criteria) with active disease not respon-
sive to ≥1 nonsteroidal anti-inflammatory drug and ≥1
disease-modifying antirheumatic drug. Active disease
was defined as ≥3 active joints (swelling or loss of
motion + pain/tenderness) and enthesitis in ≥1 location.
Pts were randomized 2:1 to receive blinded ADA
(24 mg/m2 BSA up to 40 mg every other week (wk)
[eow]) or placebo (PBO) for 12 wks followed by open-
label (OL) ADA eow up to 144 wks. The primary end-
point was% change from baseline (BL) in the number
of active joints with arthritis (AJC) at wk 12. Secondary
variables assessed included enthesitis count (EC), tender
and swollen joint counts, and American College of Rheu-
matology (ACR) Pediatric (Pedi) 30/50/70 responses.
Results are summarized through 52 wks of treatment.
Safety was assessed in terms of adverse events (AE).
Results
46 pts were randomized (31 to ADA, 15 to PBO). No pts
discontinued during the DB period; however, 7 pts early
escaped to OL ADA. Mean age was 12.9 ± 2.9 yrs. At BL,
mean duration of ERA symptoms was 2.6 ± 2.3 yrs; mean
AJC was 7.8 ± 6.6, and mean EC was 8.1 ± 8.4. The%
change from BL at wk 12 in AJC was greater in the ADA
group vs. PBO (-62.6 ± 59.5 vs -11.6 ± 100.5, P = 0.039).
Most secondary variables showed numerically greater,
but not statistically significant improvement at wk 12 in
favor of ADA vs. PBO (Table). Treatment response was
maintained with continued ADA therapy up to 52 wks
(% change from BL at wk 52 in AJC, -88.7 ± 26.1). During
the DB period AE incidence rates were similar [ADA/
PBO (%)]: any AE (67.7/53.3), serious AE (3.2/0, 1 pt in
the ADA group [abdominal pain and headache]), and
infectious AEs (29.0/20.0). Among pts who received at
least 1 dose of ADA through wk 52, any AE, serious AEs,
and infectious AEs were reported in 91.3%, 10.9%, and
76.1%, respectively. No deaths, TB, or malignancies were
reported.
Conclusion
ADA reduced the signs and symptoms of ERA at wk 12
and efficacy was sustained up to 52 wks. The safety
profile observed in pediatric patients with ERA was
consistent with that observed in children aged ≥4- years
treated for polyarticular JIA.
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Table 1
At Week 12 ADA (N = 31) PBO (N = 15)
Change from Baselinea
(mean ± SD)
# enthesitis sites (0-35)
Tender joint count (0-72)


















aLOCF. bNRI. SD, standard deviation.
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